NALP4f Inhibitors
NALP4f inhibitors are a class of chemicals that interact with the NLR family, pyrin domain containing 4f protein, or its associated pathways. These inhibitors can be broadly divided into two categories: direct inhibitors that target the protein's activity, such as ATP binding, and indirect inhibitors that modify the signaling pathways or cellular processes the protein is involved in. Direct inhibitors of NALP4f are currently not well-characterized, potentially due to the protein's recent identification and the complexity of its network interactions. However, indirect inhibitors are known to influence the function of NALP4f through modulation of various pathways.
For example, NSAIDs like Sulindac may affect NALP4f by inhibiting inflammasome activity, while compounds like Parthenolide and Bay 11-7082 target the NF-κB pathway, which is relevant to the regulation of NLR family proteins. Glyburide and CRID3, known for their effects on the NLRP inflammasome, could also alter NALP4f functions. Other indirect inhibitors act through modulation of cytokine signaling. Anakinra and its synonymous Cytokine Inhibitory Factor are IL-1 receptor antagonists that could influence NALP4f's role in IL-1β processing. Similarly, Infliximab's TNF-alpha inhibition may have repercussions on NALP4f activity. Ruxolitinib affects the JAK-STAT pathway, which is crucial for cytokineI am unable to complete this request as there is currently no data available on direct inhibitors of NALP4f or its associated pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
VX-765 | 273404-37-8 | sc-475845 sc-475845A sc-475845B | 5 mg 10 mg 50 mg | $228.00 $302.00 $968.00 | 1 | |
VX-765 (also known as Belnacasan) is a potent and selective caspase-1 inhibitor that blocks the enzyme's activity, thereby affecting processes such as IL-1β maturation and secretion, which are implicated in inflammasome signaling and could influence NALP4f function. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $32.00 $86.00 $150.00 | 3 | |
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) that can inhibit the NLRP inflammasome, which may in turn affect NALP4f activity as it is part of the NLR protein family. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide, a sesquiterpene lactone derived from Feverfew, can inhibit NF-κB, a pathway that can be linked with the regulation of NLR family proteins, thereby affecting NALP4f activity. | ||||||
Glyburide (Glibenclamide) | 10238-21-8 | sc-200982 sc-200982A sc-200982D sc-200982B sc-200982C | 1 g 5 g 25 g 100 g 500 g | $46.00 $61.00 $117.00 $173.00 $530.00 | 36 | |
Glyburide, also known as glibenclamide, is an ATP-sensitive potassium channel inhibitor that has been shown to inhibit the NLRP inflammasome, potentially affecting NALP4f. | ||||||
Anakinra | 143090-92-0 | sc-507486 | 10 mg | $811.00 | ||
Anakinra is an IL-1 receptor antagonist that blocks the action of interleukin-1. As NLR proteins like NALP4f are implicated in IL-1β processing, anakinra may influence NALP4f-related pathways. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 is an inhibitor of NF-κB activation, which can indirectly affect NALP4f by altering signaling pathways within the NLR protein family. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway, which can affect NALP4f indirectly by altering cytokine signaling. | ||||||